This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tocilizumab for Relapsing Polychondritis

This study has been withdrawn prior to enrollment.
(Tocilizumab was licenced in Canada for children, so the study was not necessary)
Information provided by (Responsible Party):
Dr Maggie Larche, McMaster Children's Hospital Identifier:
First received: April 13, 2010
Last updated: May 12, 2014
Last verified: May 2014
This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Condition Intervention Phase
Relapsing Polychondritis Drug: Tocilizumab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis

Resource links provided by NLM:

Further study details as provided by Dr Maggie Larche, McMaster Children's Hospital:

Primary Outcome Measures:
  • Efficacy of Tocilizumab [ Time Frame: 2 years ]
    Inhibition of inflammatory markers Improvement in symptoms and signs

Secondary Outcome Measures:
  • Safety of Tocilizumab [ Time Frame: 2 years ]
    Monitoring of serum lipids and liver function tests

Enrollment: 0
Study Start Date: May 2010
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Tocilizumab
    Tocilizumab 8mg/kg every 2 weeks given by IV infusion
    Other Name: Actemra

Ages Eligible for Study:   12 Years to 15 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A single patient with unremitting inflammatory relapsing polychondritis

Exclusion Criteria:

  • As this is a study in a single patient, there are no exclusions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01104480

Canada, Ontario
McMaster Children's Hospital
Hamilton, Ontario, Canada, L8N 3YZ
Sponsors and Collaborators
McMaster Children's Hospital
Principal Investigator: Maggie Larché, MD, PhD McMaster University and Children's Hospital
  More Information

Responsible Party: Dr Maggie Larche, Associate professor, McMaster Children's Hospital Identifier: NCT01104480     History of Changes
Other Study ID Numbers: RP2010
Study First Received: April 13, 2010
Last Updated: May 12, 2014

Keywords provided by Dr Maggie Larche, McMaster Children's Hospital:
Relapsing Polychondritis

Additional relevant MeSH terms:
Polychondritis, Relapsing
Cartilage Diseases
Musculoskeletal Diseases
Connective Tissue Diseases processed this record on September 20, 2017